K Number
K212071
Manufacturer
Date Cleared
2022-12-13

(529 days)

Product Code
Regulation Number
882.5891
Reference & Predicate Devices
Predicate For
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
Intended Use

Cefaly Dual Connected - OTC and Cefaly Dual Enhanced with RFID - OTC are indicated for:

  1. Acute treatment of migraine with or without aura in patients 18 years of age or older
  2. Preventative treatment of migraine in patients 18 years of age or older

Cefaly Dual Connected - Rx and Cefaly Dual Enhanced With RFID - Rx are indicated for:

  1. Acute treatment of migraine with or without aura in patients 18 years of age or older
  2. Prophylactic treatment of migraine in patients 18 years of age or older
Device Description

The Cefaly® Dual Series of devices are small, non-invasive, and portable devices meant to be worn on the forehead using a self-adhesive electrode to treat migraine similar to Cefaly® Dual (K201895 OTC and K173006 R.). The devices are similar in construction and materials and use the same components (electronics and electrical components, and firmware), including the component that comes into patient contact which is the CEFALY® Electrode. The notable differences between the Subject and Predicate devices are Bluetooth technology and mobile application for the purpose of displaying device data, the new docking station, RFID for electrode detection, audio/visual indicators, and the dimensions and the weight of the electrode.

AI/ML Overview

The provided text is a 510(k) premarket notification for the Cefaly Dual Series devices. It details the device's characteristics and compares them to predicate devices to demonstrate substantial equivalence. Crucially, this document does not contain information about a study that proves the device meets specific acceptance criteria in the format typically used for demonstrating the performance of a novel AI/ML-based medical device.

The document states:

  • "No animal testing was required to justify the differences with the corresponding Predicate Devices." (page 40)
  • "No clinical testing was required to justify the differences with the corresponding Predicate Devices." (page 40)

This indicates that the submission relies on demonstrating substantial equivalence to existing devices through bench testing and comparison of technological characteristics, rather than new clinical performance data to prove efficacy. The changes made to the device (e.g., Bluetooth, RFID, audio/visual indicators, charging system, weight, dimensions, electrode thickness, packaging) are assessed against safety and electrical standards (IEC 60601-1, IEC 60601-1-2, IEC 60601-2-10) and adhesion performance.

Therefore, I cannot provide the requested information for a study proving acceptance criteria for an AI/ML device because:

  • No acceptance criteria for an AI/ML device are listed. The document pertains to a Transcutaneous Electrical Nerve Stimulator, not a device incorporating AI/ML for diagnostic or therapeutic decision-making.
  • No study proving device performance against such criteria is presented. The "Performance Testing - Bench" section (Table 5.7.1) lists general electrical and EMC safety standards, and adhesion testing for electrodes, but not performance metrics related to migraine treatment outcomes that would typically be evaluated in a clinical trial.

Without a study described as such in the provided text, I cannot fill in the requested table or additional details. The information provided heavily focuses on hardware changes and their compliance with general safety standards, and substantiates that the functionality of the device (e.g., electrical stimulation parameters) remains equivalent to the cleared predicate devices, thus not requiring new clinical evidence of effectiveness for migraine treatment.

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

December 13, 2022

CEFALY Technology % Parul Chansoria CEO and Founder Elexes Medical Consulting, LLC 30 N Gould St Ste R Sheridan, Wyoming 82801

Re: K212071

Trade/Device Name: Cefaly Dual Enhanced with RFID - OTC, Cefaly Dual Enhanced with RFID - Rx, Cefaly Dual Connected - OTC, Cefaly Dual Connected - Rx Regulation Number: 21 CFR 882.5891 Regulation Name: Transcutaneous Electrical Nerve Stimulator To Treat Headache Regulatory Class: Class II Product Code: PCC Dated: January 6, 2022 Received: January 10, 2022

Dear Parul Chansoria:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's

{1}------------------------------------------------

requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Jitendra V. Virani -S

CDR Jitendra Virani, MS MBA Assistant Director DHT5B: Division of Neuromodulation and Physical Medicine Devices OHT5: Office of Neurological and Physical Medicine Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K212071

Device Name

Cefaly Dual Series (Cefaly Dual Enhanced with RFID - OTC, Cefaly Dual Enhanced with RFID - Rx, Cefaly Dual Connected - OTC, Cefaly Dual Connected - Rx)

Indications for Use (Describe) Cefaly Dual Connected - OTC and Cefaly Dual Enhanced with RFID - OTC are indicated for:

  1. Acute treatment of migraine with or without aura in patients 18 years of age or older 2. Preventative treatment of migraine in patients 18 years of age or older

Cefaly Dual Connected - Rx and Cefaly Dual Enhanced With RFID - Rx are indicated for:

  1. Acute treatment of migraine with or without aura in patients 18 years of age or older

  2. Prophylactic treatment of migraine in patients 18 years of age or older

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

X Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2023 See PRA Statement below.

{3}------------------------------------------------

Image /page/3/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a muted gray color. A small registration mark is present to the right of the letter "Y".

5.1. Submitter's information

CEFALY Technology, LIEGE Science Park, Rue Louis Plescia, 34, 4102 Seraing, Belgium.

Contact Person

Parul Chansoria, MS, RAC, CQA CEO & Founder, Elexes Medical Consulting Telephone: + 408-475-8091 E-mail: parul@elexes.com

Summary Prepared: December 12, 2022

5.2. Device Information

  • 5.2.1. Common/Usual name: Transcutaneous electrical nerve stimulator to treat headache Trade Name: Cefaly® Dual Connected OTC Regulation name: Transcutaneous electrical nerve stimulator to treat headache Regulation Number: 21 CFR 882.5891 Regulatory Class: Class II Classification panel: Neurology Product Code: PCC
  • 5.2.2. Common/Usual name: Transcutaneous electrical nerve stimulator to treat headache Trade Name: Cefaly® Dual Connected Rx Regulation name: Transcutaneous electrical nerve stimulator to treat headache Regulation number: 21 CFR 882.5891 Regulatory Class: Class II Classification panel: Neurology Product Code: PCC

CEFALY Technology K212071

{4}------------------------------------------------

  • 5.2.3. Common/Usual name: Transcutaneous electrical nerve stimulator to treat headache Trade Name: Cefaly® Dual Enhanced with RFID - OTC Classification name: Stimulator, Nerve, Electrical, Transcutaneous, For Migraine Regulation number: 21 CFR 882.5891 Regulatory Class: Class II Classification panel: Neurology Product Code: PCC
  • 5.2.4. Common/Usual name: Transcutaneous electrical nerve stimulator to treat headache Trade Name: Cefaly® Dual Enhanced with RFID - Rs Classification name: Stimulator, Nerve, Electrical, Transcutaneous, For Migraine Regulation number: 21 CFR 882.5891 Regulatory Class: Class II Classification panel: Neurology Product Code: PCC

5.3. Predicate Device Information

The following Predicate Devices are used:

CompanyProduct510(k)NumberSubject Device
CEFALYTechnologyCefaly® DualK173006• Cefaly® DualConnected Rx,• Cefaly® DualEnhanced withRFID Rx
CEFALYTechnologyCefaly® DualK201895• Cefaly® DualConnectedOTC,• Cefaly® Dual

{5}------------------------------------------------

Image /page/5/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a dark gray color. There is a small registered trademark symbol to the right of the letter "Y".

Enhanced withRFID OTC
---------------------------------

The Predicate Devices stated above are not subject to recall by the FDA.

5.4. Device Description

Cefaly® Dual Series by CEFALY Technology consists of Cefaly® Dual Enhanced with RFID - R., Cefaly® Dual Enhanced with RFID - OTC. Cefaly® Dual Connected - R. and Cefaly® Dual Connected - OTC. The Cefaly® Dual Series of devices are identical to the Predicate Devices Cefaly® Dual - Rx (K173006) and Cefaly® Dual - OTC (K201895).

The submission includes CEFALY® Dual Enhanced with RFID and CEFALY® Dual Connected which are indicated for Ry, are identical to the Predicate Devices CEFALY® Dual - Rx (K173006) and CEFALY® Dual Enhanced with RFID and CEFALY® Dual Connected, which are indicated for OTC, are identical to the Predicate Devices CEFALY® Dual - OTC (K201895). Additionally, all the devices in the CEFALY® Dual Series are similar in construction and materials and use the same components (electronics and electrical components, and firmware), including the component that comes into patient contact which is the CEFALY® Electrode. The notable differences between the Subject and Predicate devices are Bluetooth technology and mobile application for the purpose of displaying device data, the new docking station, RFID for electrode detection, audio/visual indicators, and the dimensions and the weight of the electrode.

The Cefaly® Dual Series of devices are small, non-invasive, and portable devices meant to be worn on the forehead using a self-adhesive electrode to treat migraine similar to Cefaly® Dual (K201895 OTC and K173006 R.).

ર.ડ. Indications for Use

Cefaly Dual Connected - OTC and Cefaly Dual Enhanced with RFID -OTC are indicated for:

    1. Acute treatment of migraine with or without aura in patients 18 years of age or older
    1. Preventative treatment of migraine in patients 18 years of age or older

{6}------------------------------------------------

Image /page/6/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a muted gray color, and the word is oriented horizontally. A small trademark symbol is located to the right of the letter "Y".

Cefaly Dual Connected – Rx and Cefaly Dual Enhanced With RFID – Rx are indicated for:

    1. Acute treatment of migraine with or without aura in patients 18 years of age or older
    1. Prophylactic treatment of migraine in patients 18 years of age or older

5.6. Technological Characteristics

5.6.1. Comparison of the Technological Characteristics between Subject Device and Predicate Device

ParametersSubject Device:Cefaly® DualConnected - OTCPredicateDevice:Cefaly® DualEquivalence
ManufacturerCEFALYTechnologyCEFALYTechnology
Device NameCEFALY® DualConnectedCEFALY® Dual-
510(k) Number-K201895-
Product codePCCPCCEquivalent
Regulation No.21 CFR 882.589121 CFR 882.5891Equivalent
Classification:IIIIEquivalent
Indications forUseThe indications foruse of CEFALY®Dual Connected foran over-the-counteruse are:The indicationsfor CEFALY®Dual for anover-the-counteruse are:Equivalent
• Acute treatmentof migraine withor without aurain patients 18years of age orolder• Preventativetreatment ofmigraine inpatients 18years of age orolder• The acutetreatment ofmigraine withor without aurain patients 18years of age orolder• The prophylactictreatment ofepisodicmigraine inpatients 18years of age orolder
MobileApplicationYesNoDifferent
BluetoothYesNoDifferent
RFID forelectrodedetectionYesNoDifferent
Charging SystemCharging dock,Power adapter andUSB Cable.Power adapterand USB CableDifferent
Power Source1 rechargeable LiPo3.7 V battery1 rechargeableLiPo 3.7 VbatteryEquivalent
Electrode MetalPlate (RFID tag)Thickness1 mm0.4 mmDifferent
Weight25 grams12 gramsDifferent
Dimensions66 mm x 47 mm x 17 mm55 mm x 40 mm x15 mmDifferent
Channels11Equivalent
TreatmentPrograms2 programs:Program 1 - The acute treatment of migraine attacks Program 2 - The prevent treatment of migraine2 programs:Program 1 - The acute treatment of migraine attacks Program 2 - The prophylactic treatment of episodic migraineEquivalent
WaveformBiphasicBiphasicEquivalent
ShapeRectangularRectangularEquivalent
Full compensatedFull compensatedEquivalent
SymmetricalSymmetricalEquivalent
Net charge (µC)per pulse00Equivalent
Maximum outputvoltage (V):
At 500 ohms88Equivalent
At 2,000 ohms3232Equivalent
At 10,000 ohms6060Equivalent
Maximum outputcurrent (mA):
At 500 ohms1616Equivalent
At 2,000 ohms1616Equivalent
At 10,000 ohms66Equivalent
Pulse duration(μs)505505Equivalent
Maximum PhaseCharge (µC) @500 Ohms44Equivalent
Type ofimpedancemonitoringsystemElectricalElectricalEquivalent
Maximumcurrent density(mA/cm2, r.m.s.)at 500 ohms2.372.37Equivalent
Treatment Programs output specifications - Program 1
Amplitude0 - 16 mA0 - 16 mAEquivalent
Pulse width250 µs, fixed250 µs, fixed
Pulse frequency100 Hz, fixed100 Hz, fixed
Session duration60 minutes60 minutes
Maximumaverage current(average absolutevalue, mA) at500 ohms0.80.8Equivalent
Maximumaverage powerdensity (W/cm²)at 500 ohms0.0000470.000047Equivalent
Treatment Programs output specifications - Program 2
Amplitude0 - 16 mA0 - 16 mA
Pulse width250 µs, fixed250 µs, fixedEquivalent
Pulse frequency60 Hz, fixed60 Hz, fixed
Session duration20 minutes20 minutes
Maximumaverage current(average absolutevalue, mA) at500 ohms0.480.48Equivalent
Maximumaverage powerdensity (W/cm²)at 500 ohms0.0000170.000017Equivalent
Audio-visual Indications
Audio Indicatorsfor low battery,Acute andPrevent Program(Low BatteryCharge),Intensity is10mA, IncreaseIntensity (ForExperiencedCEFALY Users),Bluetoothconnection anddisconnectionand electrodedetectionPresentAbsentDifferent
Visual Indicatorsfor low battery,bluetoothconnection anddisconnectionand electrodedetectionPresentAbsentDifferent
Electrode
Dimensions94 mm x 20 mm94 mm x 20 mmEquivalent
RFID tagPresentNot PresentDifferent
Electrode Metalplate1 mm0.4 mmDifferent
(tinplate)thickness
Electrode GelusedAcrylic HydrogelAcrylic HydrogelEquivalent
Packaging configurationGift BoxMade of cardboard,has a magnetic latch,artwork, and label.A white boxmade ofcardboard, nomagnetic latchand no artwork.The white boxslides inside asleeve that hasartwork andlabel.Different
Storage CaseThe storage casecontains a USBcable, chargingdock, device, usermanual, Instructionguide, andresealable bagconsisting ofelectrodesThe storage casecontains a USB,charging adapter,and electrodeinside.The device is on acardboard sheeton top of thestorage case. Usermanual(s) arebelow the case.Different
Number ofelectrodesprovided with thedeviceThree (3)One (1)Different
Electrode storageResealable bagNon- resealablebagDifferent

{7}------------------------------------------------

Image /page/7/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a dark gray color. The word is all capitalized and there is a trademark symbol after the Y.

{8}------------------------------------------------

Image /page/8/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a dark gray color. The word is all capitalized and there is a trademark symbol after the Y.

CEFALY Technology K212071

{9}------------------------------------------------

Image /page/9/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a muted gray color. The word appears to be a logo or brand name.

CEFALY Technology K212071

Page 7 of 41

{10}------------------------------------------------

Image /page/10/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a muted gray color. There is a small trademark symbol to the right of the letter "Y".

{11}------------------------------------------------

Image /page/11/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a muted gray color. The word appears to be a logo or brand name. There is a small trademark symbol to the right of the letter Y.

{12}------------------------------------------------

Image /page/12/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a dark gray color. The word appears to be a logo or brand name. There is a trademark symbol to the right of the letter Y.

{13}------------------------------------------------

Image /page/13/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a muted gray color, and the background is white. A small circle is present to the right of the letter "Y", likely indicating a registered trademark.

5.6.1.1. Similarities between Subject Device and Predicate Device

  • · The intended use is the same for the Subject and the Predicate Devices and both devices are meant for over-the-counter use.
  • Treatment Programs Waveform characteristics and output . specifications are same for both the Subject and Predicate Device.
  • The Channels are the same for both the Subject and . Predicate Devices.
  • Maximum output voltage is the same for both Subject and . Predicate Devices.
  • Maximum output current is the same for both Subject and . Predicate Devices.
  • The Power source (Battery) is the same for both Subject . and Predicate Devices.
  • . The Pulse duration, Maximum phase charge and Type of impedance monitoring system is the same for both Subject and Predicate devices.
  • . The dimensions and patient contacting material used in the electrode is same for both Subject and Predicate devices.

Differences between Subject Device and Predicate Device 5.6.1.2.

  • The usage of Mobile application and Bluetooth in Subject . Device is different from Predicate Device.
  • The RFID tag is added to electrode for Subject Device for ● electrode detection and, electrode metal plate thickness in

{14}------------------------------------------------

Subject Device (1mm) is different from Predicate Device (0.4mm).

  • The weight and dimensions of the Subject device is ● different from Predicate Device.
  • The Audio and Visual Indication for low battery, bluetooth ● and electrode detection in the Subject device is different from Predicate device.
  • The charging system in the Subject Device is different in ● terms of the design and the characteristics of input power. The Charging system of the Subject Device receives DC input from an AC/DC adapter while the charging system in the Predicate Device consists of an AC/DC adapter that receives AC input. However, both charging systems provide identical DC output voltage to the neurostimulator. The safety of the charging system in the Subject Device owing to the differences in design characteristics compared to that in the Predicate Device, is demonstrated by performance testing according to IEC 60601-1.
  • The packaging configuration of Subject and Predicate ● devices are different. However, it does not raise new questions about safety and efficacy.

5.6.2. Comparison of the Technological Characteristics between Subject Device and Predicate Device

ParametersSubject Device:Cefaly® DualConnected - RxPredicate Device:Cefaly® DualEquivalence
ManufacturerCEFALYTechnologyCEFALYTechnology
Device NameCEFALY® DualConnectedCEFALY® Dual-

CEFALY Technology K212071

{15}------------------------------------------------

Image /page/15/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a muted gray color. The word is all capitalized and there is a small circle to the right of the letter Y.

510(k) Number-K173006-
Product codePCCPCCEquivalent
Regulation No.21 CFR 882.589121 CFR 882.5891Equivalent
Classification:IIIIEquivalent
Indications for UseThe indications for use of CEFALY® Dual Connected for an Rx are:• Acute treatment of migraine with or without aura in patients 18 years of age or older• Prophylactic treatment of migraine in patients 18 years of age or olderThe indications for CEFALY® Dual for an Rx use are:• The acute treatment of migraine with or without aura in patients 18 years of age or older• The prophylactic treatment of episodic migraine in patients 18 years of age or olderEquivalent
Mobile ApplicationYesNoDifferent
BluetoothYesNoDifferent
RFID for electrode detectionYesNoDifferent
Charging SystemCharging dock,Power adapter andUSB Cable.Power adapter andUSB CableDifferent
Power Source1 rechargeable LiPo3.7 V battery1 rechargeableLiPo 3.7 V batteryEquivalent
Electrode metalplate (RFID tag)thickness1 mm0.4 mmDifferent
Weight25 grams12 gramsDifferent
Dimensions66 mm x 47 mm x 17mm55 mm x 40 mm x15 mmDifferent
Channels11Equivalent
TreatmentPrograms2 programs:Program 1 - The acute treatment of migraine attacksProgram 2 - The prevent treatment of migraine2 programs:Program 1 - The acute treatment of migraine attacksProgram 2 - The prophylactic treatment of episodic migraineEquivalent
WaveformBiphasicBiphasicEquivalent
ShapeRectangularRectangularEquivalent
Full compensatedFull compensatedEquivalent
SymmetricalSymmetricalEquivalent
Net charge (µC) per pulse00Equivalent
Maximum output voltage (V):
At 500 ohms88Equivalent
At 2,000 ohms3232
At 10,000 ohms6060
Maximum output current (mA):
At 500 ohms1616Equivalent
At 2,000 ohms1616
At 10,000 ohms66
Pulse duration (μs)505505Equivalent
Maximum Phase Charge (µC) @ 500 Ohms44Equivalent
Type of impedance monitoring systemElectricalElectricalEquivalent
Maximum currentdensity (mA/cm², r.m.s.) at 500 ohms2.372.37Equivalent
Treatment Programs output specifications - Program 1
Amplitude0 - 16 mA0 - 16 mAEquivalent
Pulse width250 µs, fixed250 µs, fixed
Pulse frequency100 Hz, fixed100 Hz, fixed
Session duration60 minutes60 minutes
Maximumaverage current(average absolutevalue, mA) at 500ohms0.80.8Equivalent
Maximumaverage powerdensity (W/cm²)at 500 ohms0.0000470.000047Equivalent
Treatment Programs output specifications - Program 2
Amplitude0 - 16 mA0 - 16 mAEquivalent
Pulse width250 µs, fixed250 µs, fixed
Pulse frequency60 Hz, fixed60 Hz, fixed
Session duration20 minutes20 minutes
Maximumaverage current(average absolute0.480.48Equivalent
value, mA) at 500 ohms
Maximum average power density (W/cm²) at 500 ohms0.0000170.000017Equivalent
Audio-visual Indications
Audio Indicators for low battery, Acute and Prevent Program (Low Battery Charge), Intensity is 10mA, Increase Intensity (For Experienced CEFALY Users), Bluetooth connection and disconnection and electrode detectionPresentAbsentDifferent
Visual Indicators for low battery, bluetooth connection and disconnection and electrode detectionPresentAbsentDifferent
Electrode
Dimensions94 mm x 20 mm94 mm x 20 mmEquivalent
RFID tagPresentNot PresentDifferent
Electrode Metalplate (tinplate)thickness1 mm0.4 mmDifferent
Electrode GelusedAcrylic HydrogelAcrylic HydrogelEquivalent
Packaging Configuration
Gift BoxMade of cardboard,has a magnetic latch,artwork, and label.A white box madeof cardboard, nomagnetic latch andno artwork. Thewhite box slidesinside a sleeve thathas artwork andlabel.Different
Storage CaseThe storage casecontains a USBcable, chargingdock, device, usermanual, Instructionguide, and resealablebag consisting ofelectrodesThe storage casecontains a USB,charging adapter,and electrodeinside.The device is on acardboard sheet ontop of the storagecase. Usermanual(s) arebelow the case.Different
Number ofelectrodesprovided with thedeviceThree (3)One (1)Different
Electrode storageResealable bagNon- resealableDifferent
bag

{16}------------------------------------------------

Image /page/16/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a muted gray color. There is a registered trademark symbol to the right of the letter Y. The background is white.

CEFALY Technology K212071

Page 14 of 41

{17}------------------------------------------------

Image /page/17/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a muted gray color. There is a small registered trademark symbol to the right of the letter "Y". The background is white.

{18}------------------------------------------------

Image /page/18/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a muted gray color. The word is all capitalized and the letters are evenly spaced. There is a small trademark symbol in the upper right corner of the image.

{19}------------------------------------------------

Image /page/19/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a muted gray color. The word is all capitalized and there is a small trademark symbol to the right of the letter Y.

{20}------------------------------------------------

Image /page/20/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a muted gray color. The word appears to be a logo or brand name. There is a trademark symbol to the right of the letter Y.

{21}------------------------------------------------

Image /page/21/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a muted gray color. The word appears to be a logo or brand name. There is a small circle to the right of the letter Y.

Similarities between Subject Device and Predicate Device 5.6.2.1.

  • The intended use is the same for the Subject and the . Predicate Devices and both devices are meant for Prescription use.
  • Treatment Programs Waveform characteristics and output ● specifications are same for both the Subject and Predicate Device.
  • The Channels are the same for both the Subject and . Predicate Devices.
  • . Maximum output voltage is the same for both Subject and Predicate Devices.
  • Maximum output current is the same for both Subject and . Predicate Devices.
  • The Power source (Battery) is the same for both Subject . and Predicate Devices.
  • The Pulse duration, Maximum phase charge and Type of . impedance monitoring system is the same for both Subject and Predicate devices.
  • . The dimensions and patient contacting material used in the electrode is same for both Subject and Predicate devices.

5.6.2.2. Differences between Subject Device and Predicate Device

  • The usage of Mobile application and Bluetooth in Subject Device is different from Predicate Device.
  • The RFID tag is added to electrode for Subject Device for . electrode detection and, electrode metal plate thickness in

{22}------------------------------------------------

Subject Device (1mm) is different from Predicate Device (0.4mm).

  • The weight and dimensions of the Subject device is ● different from Predicate Device.
  • The Audio and Visual Indication for low battery, bluetooth ● and electrode detection in the Subject device is different from Predicate device.
  • The charging system in the Subject Device is different in ● terms of the design and the characteristics of input power. The Charging system of the Subject Device receives DC input from an AC/DC adapter while the charging system in the Predicate Device consists of an AC/DC adapter that receives AC input. However, both charging systems provide identical DC output voltage to the neurostimulator. The safety of the charging system in the Subject Device owing to the differences in design characteristics compared to that in the Predicate Device, is demonstrated by performance testing according to IEC 60601-1.
  • The packaging configuration of Subject and Predicate ● devices are different. However, it does not raise new questions about safety and efficacy.

5.6.3. Comparison of the Technological Characteristics between Subject Device and Predicate Device

ParametersSubject Device:Cefaly® DualEnhanced with RFID- OTCPredicate Device:Cefaly® DualEquivalence
ManufacturerCEFALY TechnologyCEFALYTechnology
Device NameCEFALY® DualEnhanced with RFIDCEFALY® Dual-
510(k) Number-K201895-
Product codePCCPCCEquivalent
Regulation No.21 CFR 882.589121 CFR 882.5891Equivalent
Classification:IIIIEquivalent
Indications forUseThe indications foruse of CEFALY® DualEnhanced with RFIDfor anover-the-counter useare:Acute treatment ofmigraine withor without aurain patients 18years of age orolder Preventativetreatment ofmigraine inpatients 18years of age orolderThe indicationsfor CEFALY®Dual for anover-the-counteruse are:The acutetreatment ofmigraine with orwithout aura inpatients 18 yearsof age or older Theprophylactictreatment ofepisodicmigraine inpatients 18 yearsof age or olderEquivalent
MobileApplicationNoNoEquivalent
BluetoothNoNoEquivalent
RFID forelectrodedetectionYesNoDifferent
ChargingSystemCharging dock, Poweradapter and USBCablePower adapter andUSB CableDifferent
Power Source1 rechargeable LiPo3.7 V battery1 rechargeableLiPo 3.7 V batteryEquivalent
Electrode MetalPlate Thickness1 mm0.4 mmDifferent
Weight25 grams12 gramsDifferent
Dimensions66 mm x 47 mm x 17mm55 mm x 40 mm x15 mmDifferent
Channels11Equivalent
TreatmentPrograms2 programs:Program 1 - The acute treatment of migraine attacksProgram 2 - The prevent treatment of migraine2 programs:Program 1 - The acute treatment of migraine attacksProgram 2 - The prophylactic treatment of episodic migraineEquivalent
WaveformBiphasicBiphasicEquivalent
ShapeRectangularRectangularEquivalent
Full compensatedFull compensatedEquivalent
SymmetricalSymmetricalEquivalent
Net charge(µC) per pulse00
Maximumoutput voltage(V):
At 500 ohms88Equivalent
At 2,000 ohms3232
At 10,000 ohms6060
Maximumoutput current(mA):
At 500 ohms1616Equivalent
At 2,000 ohms1616
At 10,000 ohms66
Pulse duration(μs)505505Equivalent
MaximumPhase Charge(µC) @ 500Ohms44Equivalent
Type ofimpedancemonitoringsystemElectricalElectricalEquivalent
Maximumcurrent density(mA/cm²,r.m.s.) at 500ohms2.372.37Equivalent
Treatment Programs output specifications - Program 1
AmplitudePulse widthPulse frequencySessionduration0 - 16 mA250 µs, fixed100 Hz, fixed60 minutes0 - 16 mA250 µs, fixed100 Hz, fixed60 minutesEquivalent
Maximumaverage current(averageabsolute value,mA) at 500ohms0.80.8Equivalent
Maximumaverage powerdensity(W/cm²) at 500ohms0.0000470.000047Equivalent
AmplitudePulse widthPulse frequencySessionduration0 - 16 mA250 µs, fixed60 Hz, fixed20 minutes0 - 16 mA250 µs, fixed60 Hz, fixed20 minutesEquivalent
Maximumaverage current(averageabsolute value,mA) at 500ohms0.480.48Equivalent
Maximumaverage powerdensity(W/cm²) at 500ohms0.0000170.000017Equivalent
Audio-visual Indications
AudioIndicators forlow battery,Acute andPreventProgram (LowBatteryCharge),Intensity is10mA, IncreaseIntensity (ForExperiencedCEFALYUsers) andPresentAbsentDifferent
electrodedetection
VisualIndicators forlow battery andelectrodedetectionPresentAbsentDifferent
Electrode
Dimensions94 mm x 20 mm94 mm x 20 mmEquivalent
RFID tagPresentNot PresentDifferent
Electrode Metalplate (tinplate)thickness1 mm0.4 mmDifferent
Electrode GelusedAcrylic HydrogelAcrylic HydrogelEquivalent
Packaging Configuration
Gift BoxMade of cardboard,has a magnetic latch,artwork, and label.A white box madeof cardboard, nomagnetic latch andno artwork. Thewhite box slidesinside a sleeve thathas artwork andlabel.Different
Storage CaseThe storage casecontains a USB cable,charging dock, device,user manual,Instruction guide, andresealable bagconsisting ofThe storage casecontains a USB,charging adapter,and electrodeinside.The device is on aDifferent
electrodescardboard sheet ontop of the storagecase. Usermanual(s) arebelow the case.
Number ofelectrodesprovided withthe deviceThree (3)One (1)Different
ElectrodestorageResealable bagNon- resealablebagDifferent

{23}------------------------------------------------

Image /page/23/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a muted gray color. There is a small circle to the right of the "Y" which is likely a trademark symbol. The background is white.

{24}------------------------------------------------

Image /page/24/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a dark gray color. The word is all capitalized and there is a small circle to the right of the Y.

{25}------------------------------------------------

Image /page/25/Picture/0 description: The image shows the word "CEFALY" in all capital letters. The letters are a dark gray color. The font is sans-serif and the letters are evenly spaced. There is a small registered trademark symbol to the right of the letter Y.

CEFALY Technology K212071

{26}------------------------------------------------

Image /page/26/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a muted gray color. There is a small circle to the right of the letter "Y".

{27}------------------------------------------------

Image /page/27/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a muted gray color. The word is all capitalized and there is a trademark symbol after the Y. The background is white.

{28}------------------------------------------------

Image /page/28/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a muted gray color. The letters are evenly spaced and the word is centered in the image. There is a registered trademark symbol to the upper right of the letter Y.

{29}------------------------------------------------

Image /page/29/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a muted gray color. The word is all capitalized and has a small trademark symbol after the "Y".

Similarities between Subject Device and Predicate Device 5.6.3.1.

  • The intended use is the same for the Subject and Predicate Devices and both devices are meant for over-the-counter use.
  • Treatment Programs Waveform characteristics and output . specifications are same for both the Subject and Predicate Devices.
  • . The Channels are the same for both Subject and Predicate Devices.
  • Maximum output voltage is the same for both Subject and . Predicate Devices.
  • Maximum output current is the same for both Subject and . Predicate Devices.
  • The Power source (Battery) is the same for both Subject . and Predicate Devices.

{30}------------------------------------------------

Image /page/30/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a muted gray color, and the word is horizontally oriented. A small registration mark is present to the right of the letter "Y".

  • The Pulse duration, Maximum phase charge and Type of . impedance monitoring system is the same for both Subject and Predicate devices.
  • The dimensions and patient contacting material used in the . electrode is same for both Subject and Predicate devices.

Differences between Subject Device and Predicate Device 5.6.3.2.

  • The RFID tag is added to electrode for Subject Device for . electrode detection and, electrode metal plate thickness in Subject Device (1mm) is different from Predicate Device (0.4mm).
  • The weight and dimensions of the Subject device is ● different from Predicate Device.
  • The Audio and Visual Indication for low battery, bluetooth ● and electrode detection in the Subject device is different from Predicate device.
  • The charging system in the Subject Device is different in ● terms of the design and the characteristics of input power. The Charging system of the Subject Device receives DC input from an AC/DC adapter while the charging system in the Predicate Device consists of an AC/DC adapter that receives AC input. However, both charging systems provide identical DC output voltage to the neurostimulator. The safety of the charging system in the Subject Device owing to the differences in design characteristics compared to that in the Predicate Device, is demonstrated by performance testing according to IEC 60601-1.
  • The packaging configuration of Subject and Predicate ● devices are different. However, it does not raise new questions about safety and efficacy.

{31}------------------------------------------------

Image /page/31/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a muted gray color. A small registration mark is present to the right of the letter "Y".

5.6.4. Comparison of the Technological Characteristics between Subject Device and Predicate Device

ParametersSubject Device:Cefaly® DualEnhanced withRFID - RₓPredicate Device:Cefaly® DualEquivalence
ManufacturerCEFALYTechnologyCEFALYTechnology
Device NameCEFALY® DualEnhanced with RFIDCEFALY® Dual-
510(k) Number-K173006-
Product codePCCPCCEquivalent
Regulation No.21 CFR 882.589121 CFR 882.5891Equivalent
Classification:IIIIEquivalent
Indications forUseThe indications foruse of CEFALY®Dual Enhanced withRFID for an Rₓ useare:The indications forCEFALY® Dual foran Rₓ use are:• The acutetreatment ofmigraine with orwithout aura inpatients 18 yearsof age or older• The prophylactictreatment ofepisodic migraineEquivalent
Acute treatment of migraine with or without aura in patients 18 years of age or older Prophylactic treatment of migraine in patients 18 years of age or olderin patients 18 years of age or older
Mobile ApplicationNoNoEquivalent
BluetoothNoNoEquivalent
RFID for electrode detectionYesNoDifferent
Charging SystemCharging dock, USB Cable.Power adapter and USB CableDifferent
Power Source1 rechargeable LiPo 3.7 V battery1 rechargeable LiPo 3.7 V batteryEquivalent
Electrode Metal Plate (RFID tag) Thickness1 mm0.4 mmDifferent
Weight25 grams12 gramsDifferent
Dimensions66 mm x 47 mm x 17 mm55 mm x 40 mm x 15 mmDifferent
Channels11Equivalent
TreatmentPrograms2 programs:Program 1 - The acute treatment of migraine attacks Program 2 - The prevent treatment of migraine2 programs:Program 1 - The acute treatment of migraine attacks Program 2 - The prophylactic treatment of episodic migraineEquivalent
WaveformBiphasicBiphasicEquivalent
ShapeRectangularFull compensatedSymmetricalRectangularFull compensatedSymmetricalEquivalent
Net charge (μC)per pulse00Equivalent
Maximumoutput voltage8Equivalent
(V):At 500 ohmsAt 2,000 ohmsAt 10,000 ohms832
Maximumoutput current(mA):At 500 ohms1616Equivalent
At 2,000 ohmsAt 10,000 ohms16166
Pulse duration(μς)505505Equivalent
MaximumPhase Charge(μC) @ 500Ohms44Equivalent
Type ofimpedancemonitoringsystemElectricalElectricalEquivalent
Maximumcurrent density(mA/cm²,r.m.s.) at 500ohms2.372.37Equivalent
Treatment Programs output specifications - Program 1
Amplitude0 - 16 mA0 - 16 mA
Pulse width250 µs, fixed250 µs, fixed
Pulse frequency100 Hz, fixed100 Hz, fixedEquivalent
Session duration60 minutes60 minutes
Maximum average current(average absolute value,mA) at 500 ohms0.80.8Equivalent
Maximum average powerdensity (W/cm²)at 500 ohms0.0000470.000047Equivalent
Treatment Programs output specifications - Program 2
Amplitude0 - 16 mA0 - 16 mA
Pulse width250 µs, fixed250 µs, fixed
Pulse frequency60 Hz, fixed60 Hz, fixedEquivalent
Session duration20 minutes20 minutes
Maximum average current(average absolute value,mA) at 500 ohms0.480.48Equivalent
Maximumaverage powerdensity (W/cm²)at 500 ohms0.0000170.000017Equivalent
Audio-visual Indications
AudioIndicators forlow battery,Acute andPreventProgram (LowBatteryCharge),Intensity is10mA, IncreaseIntensity (ForExperiencedCEFALYUsers) andelectrodedetectionPresentAbsentDifferent
VisualIndicators forlow battery andelectrodedetectionPresentAbsentDifferent
Electrode
Dimensions94 mm x 20 mm94 mm x 20 mmEquivalent
RFID tagPresentNot PresentDifferent
Electrode Metalplate (tinplate)thickness1 mm0.4 mmDifferent
Electrode GelusedAcrylic HydrogelAcrylic HydrogelEquivalent
Packaging Configuration
Gift BoxMade of cardboard,has a magnetic latch,artwork, and label.A white box madeof cardboard, nomagnetic latch andno artwork. Thewhite box slidesinside a sleeve thathas artwork andlabel.Different
Storage CaseThe storage casecontains a USBcable, chargingdock, device, usermanual, Instructionguide, and resealablebag consisting ofelectrodesThe storage casecontains a USB,charging adapter,and electrode inside.The device is on acardboard sheet ontop of the storagecase. Usermanual(s) are belowthe case.Different
Number ofelectrodesprovided withthe deviceThree (3)One (1)Different
ElectrodestorageResealable bagNon- resealable bagDifferent

{32}------------------------------------------------

Image /page/32/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a muted gray color. The word appears to be a logo or brand name. There is a small circle to the right of the letter Y.

{33}------------------------------------------------

Image /page/33/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a dark gray color. There is a small circle to the right of the letter Y, indicating that it is a registered trademark.

{34}------------------------------------------------

Image /page/34/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a muted gray color. The word is horizontally oriented and centered in the image. There is a small trademark symbol to the right of the letter Y.

{35}------------------------------------------------

Image /page/35/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a muted gray color. A small trademark symbol is located to the right of the letter "Y".

{36}------------------------------------------------

Image /page/36/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a muted gray color. The word appears to be a logo or brand name. There is a trademark symbol to the right of the letter Y.

{37}------------------------------------------------

Image /page/37/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a muted gray color. The word is all capitalized and there is a small circle to the right of the letter Y.

{38}------------------------------------------------

Image /page/38/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a muted gray color. The word is all capitalized and there is a trademark symbol to the right of the letter Y.

Similarities between Subject Device and Predicate Device 5.6.4.1.

  • The intended use is the same for the Subject and the . Predicate Devices and both devices are meant for Prescription use.
  • . Treatment Programs - Waveform characteristics and output specifications are same for both the Subject and Predicate Device.
  • The Channels are the same for both the Subject and ● Predicate Devices.
  • Maximum output voltage is the same for both Subject and . Predicate Devices.
  • Maximum output current is the same for both Subject and . Predicate Devices.
  • The Power source (Battery) is the same for both Subject . and Predicate Devices.
  • The Pulse duration, Maximum phase charge and Type of . impedance monitoring system is the same for both Subject and Predicate devices.
  • The dimensions and patient contacting material used in the ● electrode is same for both Subject and Predicate devices.

Differences between Subject Device and Predicate Device 5.6.4.2.

  • The RFID tag is added to electrode for Subject Device for . electrode detection and, electrode metal plate thickness in Subject Device (1mm) is different from Predicate Device (0.4mm).
  • The weight and dimensions of the Subject device is ● different from Predicate Device.

{39}------------------------------------------------

  • The Audio and Visual Indication for low battery, bluetooth ● and electrode detection in the Subject device is different from Predicate device.
  • The charging system in the Subject Device is different in ● terms of the design and the characteristics of input power. The Charging system of the Subject Device receives DC input from an AC/DC adapter while the charging system in the Predicate Device consists of an AC/DC adapter that receives AC input. However, both charging systems provide identical DC output voltage to the neurostimulator. The safety of the charging system in the Subject Device owing to the differences in design characteristics compared to that in the Predicate Device, is demonstrated by performance testing according to IEC 60601-1.
  • The packaging configuration of Subject and Predicate . devices are different. However, it does not raise new questions about safety and efficacy.

5.7. PERFORMANCE TESTING - BENCH

The following bench performance testing was carried out for the devices in the Cefaly® Dual series to evaluate the safety and efficacy of the devices due to the changes made over the Predicate Device:

Table 5.7.1 : List of Tests Performed - Cefaly® Dual Series
Testing TypeTest DescriptionTest Result
Electrical Safety andElectromagneticCompatibilityTestingIEC 60601-1:2005+AMD 1 Edition 3.1, 2012-08 IEC 60601-1-2Edition 4.0Electrical safety andEMC evaluation wereperformed on the Cefaly®Dual Series according tofollowingFDA-recognized andother internationalstandards.

{40}------------------------------------------------

Image /page/40/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a muted gray color. The word appears to be a logo or brand name. There is a small trademark symbol to the right of the letter Y.

2014-02- IEC 60601-1-11 Edition 2.0 2015-01- IEC 60601-2-10 Edition 2.1 2016-04
-------------------------------------------------------------------------------------------

Adhesion testing was carried out to evaluate the adhesion performance of the Cefaly electrodes when used with the Subject Devices. The test results demonstrated that the electrodes function as intended when used and replaced in accordance with the IFU, and that there are no new or different questions related to safety and efficacy of the Subject Device.

5.8. PERFORMANCE TESTING -ANIMAL

No animal testing was required to justify the differences with the corresponding Predicate Devices.

PERFORMANCE TESTING - CLINICAL 5.9.

No clinical testing was required to justify the differences with the corresponding Predicate Devices.

5.10. COMPLIANCE WITH SPECIAL CONTROLS

Cefaly Technology complies with all applicable special controls for 21 CFR 882.5891. The special controls and corresponding compliance are listed below:

    1. The patient-contacting components of the device must be demonstrated to be biocompatible - The material and manufacturing methods remain the same to that of the Predicate Devices, therefore the biocompatibility continues to be met as per K201895.
    1. Appropriate analysis/testing must validate electromagnetic compatibility and electrical, mechanical, and thermal safety - Electrical safety and Electromagnetic compatibility testing for Cefaly® Dual Series was

{41}------------------------------------------------

Image /page/41/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a muted gray color. The word is all capitalized and there is a trademark symbol after the letter Y.

conducted in compliance with IEC 60601-1 and IEC 60601-1-2 standards and the results were found to be satisfactory.

    1. The technical parameters of the device, including waveform, output modes, maximum output voltage and current (with 500, 2,000, and 10,000 ohm loads), pulse duration, frequency, net charge (uC) per pulse, maximum phase charge at 500 ohms, maximum current density (mA/cm2, r.m.s.), maximum average current (mA), maximum average power density (W/cm2), and the type of impedance monitoring system must be fully characterized - The Cefaly® Dual Series devices have an electrical impedance monitoring system. Characterization of all the required technical parameters of the device was provided, and verification and validation tests were performed in accordance with IEC 60601-2-10 for Cefaly® Dual Series devices.
  • Electrical performance, adhesive integrity, shelf life, reusability, and 4. current distribution testing of the electrodes must be conducted - Electrical performance, adhesive integrity, reusability, and current distribution testing was conducted for Cefaly® Dual Series and the results were found to be satisfactory. Nothing that affects the shelf life of the Cefaly® Dual Series was changed, and the shelf life continues to be the same as that of the Predicate Devices.
    1. Appropriate software verification, validation, and hazard analysis must be performed - Device Hazard Analysis and Software V&V were conducted for Cefaly® Dual Series and the results were found to be satisfactory.
    1. Clinical performance data must demonstrate that the device is safe and effective as a treatment for headache in the indicated patient population -Indications for use, intended patient population, and technological characteristics of the Subject Device remain unchanged as compared to the Predicate Devices. The differences between the Subject and the Predicate Devices do not have an impact on the clinical performance and it continues to be the same as that of the Predicate Devices.
    1. Labeling for Cefaly® Dual Series devices includes the following:

{42}------------------------------------------------

  • Appropriate contraindications such as not for use in subjects with a. an implanted metallic or electronic device in the head, a cardiac pacemaker, or an implanted or wearable defibrillator.
  • b. Appropriate warnings such as not to apply the device on the neck or chest, not to use the device in the presence of electronic monitoring equipment, not to use in the bath or shower, not to use while sleeping, not to use while driving, not to use while operating machinery
  • Appropriate precautions such as the long-term effects of chronic C. use of the device are unknown.
  • d. A summary of the expected risks and benefits of using the device.
  • A summary of the clinical performance data, including information e. on the patient population for which the device has and has not been demonstrated to be effective, and any adverse events and complications.
  • f. Information on how the device operates and the typical sensations experienced during treatment
  • A detailed summary of the device technical parameters . g.
  • h. An expiration date/shelf life for the electrodes and the number of times they can be reused.
    1. Disposal instructions

For all the aforementioned (a through i) labeling requirements, appropriate information and instructions have been provided in the labeling of the Subject Device.

{43}------------------------------------------------

Image /page/43/Picture/0 description: The image shows the word "CEFALY" in a sans-serif font. The letters are a muted gray color. A small circle is present to the right of the letter "Y", likely indicating a registered trademark.

CONCLUSION 5.11.

Cefaly® Dual Series is substantially equivalent to the Predicate Device Cefaly® Dual in terms of technological characteristics, system operating range and indications for use. CEFALY Technology has concluded that the performance data obtained by evaluation of the Subject Device to the international standards demonstrate the safety and effectiveness of the Subject Device and justify substantial equivalence with the corresponding Predicate Devices.

CEFALY Technology K212071

§ 882.5891 Transcutaneous electrical nerve stimulator to treat headache.

(a)
Identification. A transcutaneous electrical nerve stimulator to treat headache is a device used to apply an electrical current to a patient's cranium through electrodes placed on the skin.(b)
Classification. Class II (special controls). The special controls for this device are:(1) The patient-contacting components of the device must be demonstrated to be biocompatible.
(2) Appropriate analysis/testing must validate electromagnetic compatibility and electrical, mechanical, and thermal safety.
(3) The technical parameters of the device, including waveform, output modes, maximum output voltage and current (with 500, 2,000, and 10,000 ohm loads), pulse duration, frequency, net charge (µC) per pulse, maximum phase charge at 500 ohms, maximum current density (mA/cm
2 , r.m.s.), maximum average current (mA), maximum average power density (W/cm2 ), and the type of impedance monitoring system must be fully characterized.(4) Electrical performance, adhesive integrity, shelf life, reusability, and current distribution testing of the electrodes must be conducted.
(5) Appropriate software verification, validation, and hazard analysis must be performed.
(6) Clinical performance data must demonstrate that the device is safe and effective as a treatment for headache in the indicated patient population.
(7) Labeling must include the following:
(i) Appropriate contraindications such as not for use in subjects with an implanted metallic or electronic device in the head, a cardiac pacemaker, or an implanted or wearable defibrillator.
(ii) Appropriate warnings such as not to apply the device on the neck or chest, not to use the device in the presence of electronic monitoring equipment, not to use in the bath or shower, not to use while sleeping, not to use while driving, not to use while operating machinery.
(iii) Appropriate precautions such as the long-term effects of chronic use of the device are unknown.
(iv) A summary of the expected risks and benefits of using the device.
(v) A summary of the clinical performance data, including information on the patient population for which the device has and has not been demonstrated to be effective, and any adverse events and complications.
(vi) Information on how the device operates and the typical sensations experienced during treatment.
(vii) A detailed summary of the device technical parameters.
(viii) An expiration date/shelf life for the electrodes and the number of times they can be reused.
(ix) Disposal instructions.